SUMO and alzheimer's disease

NeuroMolecular Medicine

Volumn 15, Issue 4, 2013, Pages 720-736

  Lee, Linda ^a   Sakurai, Mikako ^a   Matsuzaki, Shinsuke ^b,c   Arancio, Ottavio ^a   Fraser, Paul ^d  

^a NewYork Presbyterian Hospital   (United States)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Amyloid; Neurodegeneration; SUMO; Synaptic plasticity; Tau

Indexed keywords

AMYLOID BETA PROTEIN; SUMO PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; GLIA CELL; MITOCHONDRIAL DYNAMICS; NERVE CELL; NERVE CELL PLASTICITY; NERVE DEGENERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ASTROCYTES; BRAIN; HUMANS; MICE; NERVE TISSUE PROTEINS; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; SIGNAL TRANSDUCTION; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMOYLATION; SYNAPSES; TAU PROTEINS; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 84888204229     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-013-8257-7     Document Type: Review

References (164)

1. Abramov, E.; Dolev, I.; Fogel, H.; Ciccotosto, G. D.; Ruff, E.; Slutsky, I. (2009). Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nature Neuroscience, 12(12), 1567-1576.
2. Akama, K. T.; Van Eldik, L. J. (2000). Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mechanism. Journal of Biological Chemistry, 275(11), 7918-7924.
3. Akar, C. A.; Feinstein, D. L. (2009). Modulation of inducible nitric oxide synthase expression by sumoylation. Journal of Neuroinflammation, 6, 12.
4. Alzheimer's, A. (2012). Alzheimer's disease facts and figures. Alzheimer's and Dementia, 8(2), 131-168.
5. Arendt, T. (2009). Synaptic degeneration in Alzheimer's disease. [Review]. Acta Neuropathologica, 118(1), 167-179.
6. Babu, J. R.; Geetha, T.; Wooten, M. W. (2005). Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. Journal of Neurochemistry, 94(1), 192-203.
7. Ballard, C.; Gauthier, S.; Corbett, A.; Brayne, C.; Aarsland, D.; Jones, E. (2011). Alzheimer's disease. [Research Support, Non-U.S. Gov't Review]. Lancet, 377(9770), 1019-1031.
8. Bateman, R. J.; Aisen, P. S.; De Strooper, B.; Fox, N. C.; Lemere, C. A.; Ringman, J. M.; et al. (2011). Autosomal-dominant Alzheimer's disease: A review and proposal for the prevention of Alzheimer's disease. Alzheimer's Research and Therapy, 3(1), 1.
9. Benilova, I.; Karran, E.; De Strooper, B. (2012). The toxic Abeta oligomer and Alzheimer's disease: An emperor in need of clothes. Nature Neuroscience, 15(3), 349-357.
10. Bo, L.; Dawson, T. M.; Wesselingh, S.; Mork, S.; Choi, S.; Kong, P. A.; et al. (1994). Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Annals of Neurology, 36(5), 778-786.
11. Braschi, E.; Zunino, R.; McBride, H. M. (2009). MAPL is a new mitochondrial SUMO E3 ligase that regulates mitochondrial fission. EMBO Reports, 10(7), 748-754.
12. Buee, L.; Delacourte, A. (1999). Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathology, 9(4), 681-693.
13. Burdick, D.; Soreghan, B.; Kwon, M.; Kosmoski, J.; Knauer, M.; Henschen, A.; et al. (1992). Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. Journal of Biological Chemistry, 267(1), 546-554.
14. Cerveny, K. L.; Tamura, Y.; Zhang, Z.; Jensen, R. E.; Sesaki, H. (2007). Regulation of mitochondrial fusion and division. Trends in Cell Biology, 17(11), 563-569.
15. Chao, H. W.; Hong, C. J.; Huang, T. N.; Lin, Y. L.; Hsueh, Y. P. (2008). SUMOylation of the MAGUK protein CASK regulates dendritic spinogenesis. [Research Support, Non-U.S. Gov't]. Journal of Cell Biology, 182(1), 141-155.
16. Chen, H.; Chan, D. C. (2009). Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Human Molecular Genetics, 18(R2), R169-R176.
17. Cisse, M.; Halabisky, B.; Harris, J.; Devidze, N.; Dubal, D. B.; Sun, B.; et al. (2011). Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature, 469(7328), 47-52.
18. Citron, M. (2010). Alzheimer's disease: Strategies for disease modification. [Review]. Nature Reviews Drug Discovery, 9(5), 387-398.
19. Comerford, K. M.; Leonard, M. O.; Karhausen, J.; Carey, R.; Colgan, S. P.; Taylor, C. T. (2003). Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 100(3), 986-991.
20. Corder, E. H.; Saunders, A. M.; Strittmatter, W. J.; Schmechel, D. E.; Gaskell, P. C.; Small, G. W.; et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261(5123), 921-923.
21. Corneveaux, J. J.; Myers, A. J.; Allen, A. N.; Pruzin, J. J.; Ramirez, M.; Engel, A.; et al. (2010). Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Human Molecular Genetics, 19(16), 3295-3301.
22. Costantini, C.; Ko, M. H.; Jonas, M. C.; Puglielli, L. (2007). A reversible form of lysine acetylation in the ER and Golgi lumen controls the molecular stabilization of BACE1. The Biochemical Journal, 407(3), 383-395.
23. Craig, T. J.; Jaafari, N.; Petrovic, M. M.; Rubin, P. P.; Mellor, J. R.; Henley, J. M. (2012). Homeostatic synaptic scaling is regulated by protein SUMOylation. The Journal of Biological Chemistry, 287(27), 22781-22788.
24. Dadke, S.; Cotteret, S.; Yip, S. C.; Jaffer, Z. M.; Haj, F.; Ivanov, A.; et al. (2007). Regulation of protein tyrosine phosphatase 1B by sumoylation. Nature Cell Biology, 9(1), 80-85.
25. David, D. C.; Layfield, R.; Serpell, L.; Narain, Y.; Goedert, M.; Spillantini, M. G. (2002). Proteasomal degradation of tau protein. Journal of Neurochemistry, 83(1), 176-185.
26. Davies, C. A.; Mann, D. M.; Sumpter, P. Q.; Yates, P. O. (1987). A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. Journal of the Neurological Sciences, 78(2), 151-164.
27. De Strooper, B.; Iwatsubo, T.; Wolfe, M. S. (2012). Presenilins and gamma-secretase: Structure, function, and role in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2(1), a006304.
28. DeKosky, S. T.; Scheff, S. W. (1990). Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Annals of Neurology, 27(5), 457-464.
29. Dodart, J. C.; Bales, K. R.; Gannon, K. S.; Greene, S. J.; DeMattos, R. B.; Mathis, C.; et al. (2002). Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nature Neuroscience, 5(5), 452-457.
30. Donkin, J. J.; Stukas, S.; Hirsch-Reinshagen, V.; Namjoshi, D.; Wilkinson, A.; May, S.; et al. (2010). ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. Journal of Biological Chemistry, 285(44), 34144-34154.
31. Dorval, V.; Fraser, P. E. (2006). Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. Journal of Biological Chemistry, 281(15), 9919-9924.
32. Dorval, V.; Fraser, P. E. (2007). SUMO on the road to neurodegeneration. Biochimica et Biophysica Acta, 1773(6), 694-706.
33. Dorval, V.; Mazzella, M. J.; Mathews, P. M.; Hay, R. T.; Fraser, P. E. (2007). Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins. The Biochemical Journal, 404(2), 309-316.
34. Dougherty, J. J.; Wu, J.; Nichols, R. A. (2003). Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. Journal of Neuroscience, 23(17), 6740-6747.
35. Endoh, M.; Maiese, K.; Wagner, J. (1994). Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. Brain Research, 651(1-2), 92-100.
36. Eun Jeoung, L.; Sung Hee, H.; Jaesun, C.; Sung Hwa, S.; Kwang Hum, Y.; Min Kyoung, K.; et al. (2008). Regulation of glycogen synthase kinase 3beta functions by modification of the small ubiquitin-like modifier. Open Biochemistry Journal, 2, 67-76.
37. Feligioni, M.; Nishimune, A.; Henley, J. M. (2009). Protein SUMOylation modulates calcium influx and glutamate release from presynaptic terminals. European Journal of Neuroscience, 29(7), 1348-1356.
38. Figueroa-Romero, C.; Iñiguez-Lluhí, J. A.; Stadler, J.; Chang, C.-R.; Arnoult, D.; Keller, P. J.; et al. (2009). SUMOylation of the mitochondrial fission protein Drp1 occurs at multiple nonconsensus sites within the B domain and is linked to its activity cycle. The FASEB Journal, 23(11), 3917-3927.
39. Fitz, N. F.; Cronican, A.; Pham, T.; Fogg, A.; Fauq, A. H.; Chapman, R.; et al. (2010). Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. Journal of Neuroscience, 30(20), 6862-6872.
40. Galea, E.; Feinstein, D. L.; Reis, D. J. (1992). Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures. Proceedings of the National Academy of Sciences of the United States of America, 89(22), 10945-10949.
41. Ghisletti, S.; Huang, W.; Ogawa, S.; Pascual, G.; Lin, M. E.; Willson, T. M.; et al. (2007). Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Molecular Cell, 25(1), 57-70.
42. Giorgino, F.; de Robertis, O.; Laviola, L.; Montrone, C.; Perrini, S.; McCowen, K. C.; et al. (2000). The sentrin-conjugating enzyme mUbc9 interacts with GLUT4 and GLUT1 glucose transporters and regulates transporter levels in skeletal muscle cells. Proceedings of the National Academy of Sciences of the United States of America, 97(3), 1125-1130.
43. Gocke, C. B.; Yu, H.; Kang, J. (2005). Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates. Journal of Biological Chemistry, 280(6), 5004-5012.
44. Goedert, M.; Spillantini, M. G.; Cairns, N. J.; Crowther, R. A. (1992). Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron, 8(1), 159-168.
45. Gowran, A.; Murphy, C. E.; Campbell, V. A. (2009). Delta(9)- tetrahydrocannabinol regulates the p53 post-translational modifiers Murine double minute 2 and the Small Ubiquitin MOdifier protein in the rat brain. FEBS Letters, 583(21), 3412-3418.
46. Grilli, M.; Lagomarsino, F.; Zappettini, S.; Preda, S.; Mura, E.; Govoni, S.; et al. (2010). Specific inhibitory effect of amyloid-beta on presynaptic muscarinic receptor subtypes modulating neurotransmitter release in the rat nucleus accumbens. Neuroscience, 167(2), 482-489.
47. Grupe, A.; Abraham, R.; Li, Y.; Rowland, C.; Hollingworth, P.; Morgan, A.; et al. (2007). Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Human Molecular Genetics, 16(8), 865-873.
48. Guo, C.; Hildick, K. L.; Luo, J.; Dearden, L.; Wilkinson, K. A.; Henley, J. M. (2013). SENP3-mediated deSUMOylation of dynamin-related protein 1 promotes cell death following ischaemia. The EMBO Journal, 32(11), 1514-1528.
49. Haass, C.; Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nature Reviews Molecular Cell Biology, 8(2), 101-112.
50. Harder, Z.; Zunino, R.; McBride, H. (2004). Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission. Current Biology, 14(4), 340-345.
51. Heneka, M. T.; Sastre, M.; Dumitrescu-Ozimek, L.; Hanke, A.; Dewachter, I.; Kuiperi, C.; et al. (2005). Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain, 128(Pt 6), 1442-1453.
52. Heneka, M. T.; Wiesinger, H.; Dumitrescu-Ozimek, L.; Riederer, P.; Feinstein, D. L.; Klockgether, T. (2001). Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. Journal of Neuropathology and Experimental Neurology, 60(9), 906-916.
53. Hewett, S. J.; Corbett, J. A.; McDaniel, M. L.; Choi, D. W. (1993). Interferon-gamma and interleukin-1 beta induce nitric oxide formation from primary mouse astrocytes. Neuroscience Letters, 164(1-2), 229-232.
54. Hilbich, C.; Kisters-Woike, B.; Reed, J.; Masters, C. L.; Beyreuther, K. (1991). Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. Journal of Molecular Biology, 218(1), 149-163.
55. Hirai, K.; Aliev, G.; Nunomura, A.; Fujioka, H.; Russell, R. L.; Atwood, C. S.; et al. (2001). Mitochondrial abnormalities in Alzheimer's disease. The Journal of Neuroscience, 21(9), 3017-3023.
56. Hollingworth, P.; Harold, D.; Sims, R.; Gerrish, A.; Lambert, J. C.; Carrasquillo, M. M.; et al. (2011). Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 43(5), 429-435.
57. Holtzman, D. M.; Morris, J. C.; Goate, A. M. (2011a). Alzheimer's disease: The challenge of the second century. Science Translational Medicine, 3(77), 77sr71.
58. Holtzman, D. M.; Morris, J. C.; Goate, A. M. (2011b). Alzheimer's disease: The challenge of the second century. [Review]. Science Translational Medicine, 3(77), 77sr71.
59. Hoppe, J. B.; Rattray, M.; Tu, H.; Salbego, C. G.; Cimarosti, H. (2013). SUMO-1 conjugation blocks beta-amyloid-induced astrocyte reactivity. Neuroscience Letters, 546, 51-56.
60. Hsieh, H.; Boehm, J.; Sato, C.; Iwatsubo, T.; Tomita, T.; Sisodia, S.; et al. (2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron, 52(5), 831-843.
61. Hu, J.; Akama, K. T.; Krafft, G. A.; Chromy, B. A.; Van Eldik, L. J. (1998). Amyloid-beta peptide activates cultured astrocytes: Morphological alterations, cytokine induction and nitric oxide release. Brain Research, 785(2), 195-206.
62. Jarrett, J. T.; Berger, E. P.; Lansbury, P. T, Jr. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry, 32(18), 4693-4697.
63. Jarrett, J. T.; Lansbury, P. T, Jr. (1993). Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell, 73(6), 1055-1058.
64. Jiang, Q.; Lee, C. Y.; Mandrekar, S.; Wilkinson, B.; Cramer, P.; Zelcer, N.; et al. (2008). ApoE promotes the proteolytic degradation of Abeta. Neuron, 58(5), 681-693.
65. Jin, M.; Shepardson, N.; Yang, T.; Chen, G.; Walsh, D.; Selkoe, D. J. (2011). Soluble amyloid {beta}-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proceedings of the National Academy of Sciences of the United States of America, 108(14), 5819-5824.
66. Johnson, E. S.; Gupta, A. A. (2001). An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell, 106(6), 735-744.
67. Kauwe, J. S.; Wang, J.; Mayo, K.; Morris, J. C.; Fagan, A. M.; Holtzman, D. M.; et al. (2009). Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics, 10(1), 13-17.
68. Khan, G. M.; Tong, M.; Jhun, M.; Arora, K.; Nichols, R. A. (2010). Beta-Amyloid activates presynaptic alpha7 nicotinic acetylcholine receptors reconstituted into a model nerve cell system: Involvement of lipid rafts. (Research Support, N.I.H.; Extramural Research Support, Non-U.S. Gov't). The European Journal of Neuroscience, 31(5), 788-796.
69. Kim, J.; Basak, J. M.; Holtzman, D. M. (2009). The role of apolipoprotein E in Alzheimer's disease. Neuron, 63(3), 287-303.
70. Koldamova, R. P.; Lefterov, I. M.; Staufenbiel, M.; Wolfe, D.; Huang, S.; Glorioso, J. C.; et al. (2005). The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. Journal of Biological Chemistry, 280(6), 4079-4088.
71. Lacor, P. N.; Buniel, M. C.; Chang, L.; Fernandez, S. J.; Gong, Y.; Viola, K. L.; et al. (2004). Synaptic targeting by Alzheimer's-related amyloid beta oligomers. Journal of Neuroscience, 24(45), 10191-10200.
72. Lacor, P. N.; Buniel, M. C.; Furlow, P. W.; Clemente, A. S.; Velasco, P. T.; Wood, M.; et al. (2007). Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. Journal of Neuroscience, 27(4), 796-807.
73. Lane, R. F.; Shineman, D. W.; Steele, J. W.; Lee, L. B.; Fillit, H. M. (2012). Beyond amyloid: The future of therapeutics for Alzheimer's disease. Advances in Pharmacology, 64, 213-271.
74. Larson, M. E.; Lesne, S. E. (2012). Soluble Abeta oligomer production and toxicity. Journal of Neurochemistry, 120(Suppl 1), 125-139.
75. Lauren, J.; Gimbel, D. A.; Nygaard, H. B.; Gilbert, J. W.; Strittmatter, S. M. (2009). Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature, 457(7233), 1128-1132.
76. Lee, S. C.; Dickson, D. W.; Liu, W.; Brosnan, C. F. (1993). Induction of nitric oxide synthase activity in human astrocytes by interleukin-1 beta and interferon-gamma. Journal of Neuroimmunology, 46(1-2), 19-24.
77. Lee, M. J.; Lee, J. H.; Rubinsztein, D. C. (2013). Tau degradation: The ubiquitin-proteasome system versus the autophagy-lysosome system. Progress in Neurobiology, 105, 49-59.
78. Lee, G. W.; Melchior, F.; Matunis, M. J.; Mahajan, R.; Tian, Q.; Anderson, P. (1998). Modification of Ran GTPase-activating protein by the small ubiquitin-related modifier SUMO-1 requires Ubc9, an E2-type ubiquitin- conjugating enzyme homologue. Journal of Biological Chemistry, 273(11), 6503-6507.
79. Li, S.; Hong, S.; Shepardson, N. E.; Walsh, D. M.; Shankar, G. M.; Selkoe, D. (2009). Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron, 62(6), 788-801.
80. Li, Y.; Wang, H.; Wang, S.; Quon, D.; Liu, Y. W.; Cordell, B. (2003). Positive and negative regulation of APP amyloidogenesis by sumoylation. Proceedings of the National Academy of Sciences of the United States of America, 100(1), 259-264.
81. Lim, G. P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S. A.; Cole, G. M. (2001). The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. The Journal of Neuroscience, 21(21), 8370-8377.
82. Lin, M. T.; Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature, 443(7113), 787-795.
83. Loriol, C.; Khayachi, A.; Poupon, G.; Gwizdek, C.; Martin, S. (2013). Activity-dependent regulation of the sumoylation machinery in rat hippocampal neurons. Biology of the Cell, 105(1), 30-45.
84. Manczak, M.; Calkins, M. J.; Reddy, P. H. (2011). Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: Implications for neuronal damage. Human Molecular Genetics, 20(13), 2495-2509.
85. Mandelkow, E. M.; Mandelkow, E. (2012). Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harbor Perspectives in Medicine, 2(7), a006247.
86. Mandrekar-Colucci, S.; Karlo, J. C.; Landreth, G. E. (2012). Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. Journal of Neuroscience, 32(30), 10117-10128.
87. Martin, S.; Nishimune, A.; Mellor, J. R.; Henley, J. M. (2007). SUMOylation regulates kainate-receptor-mediated synaptic transmission. Nature, 447(7142), 321-325.
88. Masliah, E.; Mallory, M.; Alford, M.; DeTeresa, R.; Hansen, L. A.; McKeel, D. W, Jr, et al. (2001). Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology, 56(1), 127-129.
89. Masliah, E.; Mallory, M.; Hansen, L.; DeTeresa, R.; Alford, M.; Terry, R. (1994). Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neuroscience Letters, 174(1), 67-72.
90. Masters, C. L.; Selkoe, D. J. (2012). Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 2(6), a006262.
91. Masters, C. L.; Simms, G.; Weinman, N. A.; Multhaup, G.; McDonald, B. L.; Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences of the United States of America, 82(12), 4245-4249.
92. Mayeux, R.; Stern, Y. (2012). Epidemiology of Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 2(8), a006239.
93. Mc Donald, J. M.; Savva, G. M.; Brayne, C.; Welzel, A. T.; Forster, G.; Shankar, G. M.; et al. (2010). The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain, 133(Pt 5), 1328-1341.
94. McLean, C. A.; Cherny, R. A.; Fraser, F. W.; Fuller, S. J.; Smith, M. J.; Beyreuther, K.; et al. (1999). Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Annals of Neurology, 46(6), 860-866.
95. McMillan, L. E.; Brown, J. T.; Henley, J. M.; Cimarosti, H. (2011). Profiles of SUMO and ubiquitin conjugation in an Alzheimer's disease model. Neuroscience Letters, 502(3), 201-208.
96. Mishra, R. K.; Jatiani, S. S.; Kumar, A.; Simhadri, V. R.; Hosur, R. V.; Mittal, R. (2004). Dynamin interacts with members of the sumoylation machinery. Journal of Biological Chemistry, 279(30), 31445-31454.
97. Moller, H. J.; Graeber, M. B. (1998). The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. European Archives of Psychiatry and Clinical Neuroscience, 248(3), 111-122.
98. Moreno, H.; Yu, E.; Pigino, G.; Hernandez, A. I.; Kim, N.; Moreira, J. E.; et al. (2009). Synaptic transmission block by presynaptic injection of oligomeric amyloid beta. Proceedings of the National Academy of Sciences of the United States of America, 106(14), 5901-5906.
99. Mori, H.; Kondo, J.; Ihara, Y. (1987). Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science, 235(4796), 1641-1644.
100. Mucke, L.; Selkoe, D. J. (2012). Neurotoxicity of amyloid beta-protein: Synaptic and network dysfunction. Cold Spring Harbor Perspectives in Medicine, 2(7), a006338.
101. Mura, E.; Preda, S.; Govoni, S.; Lanni, C.; Trabace, L.; Grilli, M.; et al. (2010). Specific neuromodulatory actions of amyloid-beta on dopamine release in rat nucleus accumbens and caudate putamen. Journal of Alzheimer's Disease, 19(3), 1041-1053.
102. Naj, A. C.; Jun, G.; Beecham, G. W.; Wang, L. S.; Vardarajan, B. N.; Buros, J.; et al. (2011). Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 43(5), 436-441.
103. Nistico, R.; Pignatelli, M.; Piccinin, S.; Mercuri, N. B.; Collingridge, G. (2012). Targeting synaptic dysfunction in Alzheimer's disease therapy. Molecular Neurobiology, 46(3), 572-587.
104. Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. (2004). Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Journal of Neuroscience Research, 75(6), 742-750.
105. Palop, J. J.; Mucke, L. (2010). Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: From synapses toward neural networks. Nature Neuroscience, 13(7), 812-818.
106. Pascual, G.; Fong, A. L.; Ogawa, S.; Gamliel, A.; Li, A. C.; Perissi, V.; et al. (2005). A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature, 437(7059), 759-763.
107. Pehar, M.; Puglielli, L. (2013). Lysine acetylation in the lumen of the ER: A novel and essential function under the control of the UPR. Biochimica et Biophysica Acta, 1833(3), 686-697.
108. Perry, G.; Friedman, R.; Shaw, G.; Chau, V. (1987). Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proceedings of the National Academy of Sciences of the United States of America, 84(9), 3033-3036.
109. Pountney, D. L.; Huang, Y.; Burns, R. J.; Haan, E.; Thompson, P. D.; Blumbergs, P. C.; et al. (2003). SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Experimental Neurology, 184(1), 436-446.
110. Preda, S.; Govoni, S.; Lanni, C.; Racchi, M.; Mura, E.; Grilli, M.; et al. (2008). Acute beta-amyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens. Neuropsychopharmacology, 33(5), 1062-1070.
111. Querfurth, H. W.; LaFerla, F. M. (2010). Alzheimer's disease. [Review]. The New England Journal of Medicine, 362(4), 329-344.
112. Rajan, S.; Plant, L. D.; Rabin, M. L.; Butler, M. H.; Goldstein, S. A. (2005). Sumoylation silences the plasma membrane leak K + channel K2P1. Cell, 121(1), 37-47.
113. Reddy, P. H.; Beal, M. F. (2008). Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer's disease. Trends in molecular medicine, 14(2), 45.
114. Renner, M.; Lacor, P. N.; Velasco, P. T.; Xu, J.; Contractor, A.; Klein, W. L.; et al. (2010). Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron, 66(5), 739-754.
115. Riddell, D. R.; Zhou, H.; Comery, T. A.; Kouranova, E.; Lo, C. F.; Warwick, H. K.; et al. (2007). The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Molecular and Cellular Neuroscience, 34(4), 621-628.
116. Rodriguez, M. S.; Dargemont, C.; Hay, R. T. (2001). SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. Journal of Biological Chemistry, 276(16), 12654-12659.
117. Rui, H. L.; Fan, E.; Zhou, H. M.; Xu, Z.; Zhang, Y.; Lin, S. C. (2002). SUMO-1 modification of the C-terminal KVEKVD of Axin is required for JNK activation but has no effect on Wnt signaling. Journal of Biological Chemistry, 277(45), 42981-42986.
118. Saitoh, H.; Hinchey, J. (2000). Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. Journal of Biological Chemistry, 275(9), 6252-6258.
119. Sarge, K. D.; Park-Sarge, O. K. (2011). SUMO and its role in human diseases. [Research Support, N.I.H.; Extramural Review]. International review of cell and molecular biology, 288, 167-183.
120. Scheff, S. W.; Price, D. A.; Schmitt, F. A.; DeKosky, S. T.; Mufson, E. J. (2007). Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology, 68(18), 1501-1508.
121. Scheff, S. W.; Price, D. A.; Schmitt, F. A.; Mufson, E. J. (2006). Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 27(10), 1372-1384.
122. Scheibel, M. E.; Lindsay, R. D.; Tomiyasu, U.; Scheibel, A. B. (1975). Progressive dendritic changes in aging human cortex. Experimental Neurology, 47(3), 392-403.
123. Schweers, O.; Schonbrunn-Hanebeck, E.; Marx, A.; Mandelkow, E. (1994). Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure. Journal of Biological Chemistry, 269(39), 24290-24297.
124. Selkoe, D. J. (1996). Amyloid beta-protein and the genetics of Alzheimer's disease. Journal of Biological Chemistry, 271(31), 18295-18298.
125. Selkoe, D. J. (2001). Alzheimer's disease: Genes, proteins, and therapy. Physiological Reviews, 81(2), 741-766.
126. Selkoe, D. J. (2002). Alzheimer's disease is a synaptic failure. Science, 298(5594), 789-791.
127. Selkoe, D. J. (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behavioural Brain Research, 192(1), 106-113.
128. Serrano-Pozo, A.; Frosch, M. P.; Masliah, E.; Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 1(1), a006189.
129. Shalizi, A.; Gaudilliere, B.; Yuan, Z.; Stegmuller, J.; Shirogane, T.; Ge, Q.; et al. (2006). A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science, 311(5763), 1012-1017.
130. Shankar, G. M.; Bloodgood, B. L.; Townsend, M.; Walsh, D. M.; Selkoe, D. J.; Sabatini, B. L. (2007). Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. Journal of Neuroscience, 27(11), 2866-2875.
131. Shankar, G. M.; Li, S.; Mehta, T. H.; Garcia-Munoz, A.; Shepardson, N. E.; Smith, I.; et al. (2008). Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Medicine, 14(8), 837-842.
132. Shimura, H.; Schwartz, D.; Gygi, S. P.; Kosik, K. S. (2004). CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. The Journal of Biological Chemistry, 279(6), 4869-4876.
133. Siddiqua, A.; Luo, Y.; Meyer, V.; Swanson, M. A.; Yu, X.; Wei, G.; et al. (2012). Conformational basis for asymmetric seeding barrier in filaments of three- and four-repeat tau. Journal of the American Chemical Society, 134(24), 10271-10278.
134. Snyder, E. M.; Nong, Y.; Almeida, C. G.; Paul, S.; Moran, T.; Choi, E. Y.; et al. (2005). Regulation of NMDA receptor trafficking by amyloid-beta. Nature Neuroscience, 8(8), 1051-1058.
135. Stine, W. B, Jr, Dahlgren, K. N.; Krafft, G. A.; LaDu, M. J. (2003). In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. Journal of Biological Chemistry, 278(13), 11612-11622.
136. Sturchler, E.; Galichet, A.; Weibel, M.; Leclerc, E.; Heizmann, C. W. (2008). Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. Journal of Neuroscience, 28(20), 5149-5158.
137. Takahashi, K.; Ishida, M.; Komano, H.; Takahashi, H. (2008). SUMO-1 immunoreactivity co-localizes with phospho-Tau in APP transgenic mice but not in mutant Tau transgenic mice. Neuroscience Letters, 441(1), 90-93.
138. Tanzi, R. E. (2012). The genetics of Alzheimer disease. Cold Spring Harbor Perspectives in Medicine, 2(10), a006296.
139. Tatham, M. H.; Geoffroy, M. C.; Shen, L.; Plechanovova, A.; Hattersley, N.; Jaffray, E. G.; et al. (2008). RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nature Cell Biology, 10(5), 538-546.
140. Terry, R. D.; Masliah, E.; Salmon, D. P.; Butters, N.; DeTeresa, R.; Hill, R.; et al. (1991). Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Annals of Neurology, 30(4), 572-580.
141. Thompson, P. M.; Hayashi, K. M.; de Zubicaray, G.; Janke, A. L.; Rose, S. E.; Semple, J.; et al. (2003). Dynamics of gray matter loss in Alzheimer's disease. Journal of Neuroscience, 23(3), 994-1005.
142. Tirard, M.; Hsiao, H. H.; Nikolov, M.; Urlaub, H.; Melchior, F.; Brose, N. (2012). In vivo localization and identification of SUMOylated proteins in the brain of His6-HA-SUMO1 knock-in mice. Proceedings of the National Academy of Sciences of the United States of America, 109(51), 21122-21127.
143. Toledo, E. M.; Inestrosa, N. C. (2010). Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Molecular Psychiatry, 15(3), 272-285, 228.
144. Um, J. W.; Chung, K. C. (2006). Functional modulation of parkin through physical interaction with SUMO-1. Journal of Neuroscience Research, 84(7), 1543-1554.
145. van Niekerk, E. A.; Willis, D. E.; Chang, J. H.; Reumann, K.; Heise, T.; Twiss, J. L. (2007). Sumoylation in axons triggers retrograde transport of the RNA-binding protein La. Proceedings of the National Academy of Sciences of the United States of America, 104(31), 12913-12918.
146. Wallace, M. N.; Geddes, J. G.; Farquhar, D. A.; Masson, M. R. (1997). Nitric oxide synthase in reactive astrocytes adjacent to beta-amyloid plaques. Experimental Neurology, 144(2), 266-272.
147. Walsh, D. M.; Klyubin, I.; Fadeeva, J. V.; Cullen, W. K.; Anwyl, R.; Wolfe, M. S.; et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416(6880), 535-539.
148. Wang, H. Y.; Lee, D. H.; D'Andrea, M. R.; Peterson, P. A.; Shank, R. P.; Reitz, A. B. (2000). beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. Journal of Biological Chemistry, 275(8), 5626-5632.
149. Wang, X.; Su, B.; Lee, H. G.; Li, X.; Perry, G.; Smith, M. A.; et al. (2009). Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. Journal of Neuroscience, 29(28), 9090-9103.
150. Wang, Q.; Walsh, D. M.; Rowan, M. J.; Selkoe, D. J.; Anwyl, R. (2004). Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. Journal of Neuroscience, 24(13), 3370-3378.
151. Wang, J. Z.; Xia, Y. Y.; Grundke-Iqbal, I.; Iqbal, K. (2013). Abnormal hyperphosphorylation of tau: Sites, regulation, and molecular mechanism of neurofibrillary degeneration. Journal of Alzheimer's Disease, 33(Suppl 1), S123-S139.
152. Weeraratna, A. T.; Kalehua, A.; Deleon, I.; Bertak, D.; Maher, G.; Wade, M. S.; et al. (2007). Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues. Experimental Cell Research, 313(3), 450-461.
153. Wei, W.; Nguyen, L. N.; Kessels, H. W.; Hagiwara, H.; Sisodia, S.; Malinow, R. (2010). Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nature Neuroscience, 13(2), 190-196.
154. Weinreb, P. H.; Zhen, W.; Poon, A. W.; Conway, K. A.; Lansbury, P. T, Jr. (1996). NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 35(43), 13709-13715.
155. West, M. J.; Coleman, P. D.; Flood, D. G.; Troncoso, J. C. (1994). Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet, 344(8925), 769-772.
156. Wilkinson, K. A.; Nakamura, Y.; Henley, J. M. (2010). Targets and consequences of protein SUMOylation in neurons. Brain Research Reviews, 64(1), 195-212.
157. Wyss-Coray, T.; Rogers, J. (2012). Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harbor Perspectives in Medicine, 2(1), a006346.
158. Yan, S. D.; Chen, X.; Fu, J.; Chen, M.; Zhu, H.; Roher, A.; et al. (1996). RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature, 382(6593), 685-691.
159. Yang, F.; Lim, G. P.; Begum, A. N.; Ubeda, O. J.; Simmons, M. R.; Ambegaokar, S. S.; et al. (2005). Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. Journal of Biological Chemistry, 280(7), 5892-5901.
160. Yang, Q. G.; Wang, F.; Zhang, Q.; Xu, W. R.; Chen, Y. P.; Chen, G. H. (2012). Correlation of increased hippocampal Sumo3 with spatial learning ability in old C57BL/6 mice. Neuroscience Letter, 518(2), 75-79.
161. Yun, S. M.; Cho, S. J.; Song, J. C.; Song, S. Y.; Jo, S. A.; Jo, C.; et al. (2013). SUMO1 modulates Abeta generation via BACE1 accumulation. Neurobiology of Aging, 34(3), 650-662.
162. Zelcer, N.; Khanlou, N.; Clare, R.; Jiang, Q.; Reed-Geaghan, E. G.; Landreth, G. E.; et al. (2007). Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proceedings of the National Academy of Sciences of the United States of America, 104(25), 10601-10606.
163. Zhang, Y. Q.; Sarge, K. D. (2008). Sumoylation of amyloid precursor protein negatively regulates Abeta aggregate levels. Biochemical and Biophysical Research Communications, 374(4), 673-678.
164. Zunino, R.; Schauss, A.; Rippstein, P.; Andrade-Navarro, M.; McBride, H. M. (2007). The SUMO protease SENP5 is required to maintain mitochondrial morphology and function. Journal of Cell Science, 120(Pt 7), 1178-1188.